{"organizations": [], "uuid": "98cf006149d29a32877296c9f8661b00c1d20763", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-albireo-announces-agreement-with-h/brief-albireo-announces-agreement-with-healthcare-royalty-partners-idUSFWN1OY0CA", "country": "US", "domain_rank": 408, "title": "BRIEF-Albireo Announces Agreement With Healthcare Royalty Partners", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-03T15:08:00.000+02:00", "replies_count": 0, "uuid": "98cf006149d29a32877296c9f8661b00c1d20763"}, "author": "", "url": "https://www.reuters.com/article/brief-albireo-announces-agreement-with-h/brief-albireo-announces-agreement-with-healthcare-royalty-partners-idUSFWN1OY0CA", "ord_in_thread": 0, "title": "BRIEF-Albireo Announces Agreement With Healthcare Royalty Partners", "locations": [], "entities": {"persons": [{"name": "elobix", "sentiment": "none"}], "locations": [{"name": "japan", "sentiment": "none"}], "organizations": [{"name": "healthcare royalty partners reuters", "sentiment": "negative"}, {"name": "healthcare royalty partners", "sentiment": "negative"}, {"name": "hcr", "sentiment": "none"}, {"name": "albireo pharma inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "albireo pharma", "sentiment": "none"}, {"name": "albireo pharma inc", "sentiment": "none"}, {"name": "ea pharma", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 08 PM / in 14 minutes BRIEF-Albireo Announces Agreement With Healthcare Royalty Partners Reuters Staff \nJan 3 (Reuters) - Albireo Pharma Inc: \n* ALBIREO ANNOUNCES ROYALTY MONETIZATION AGREEMENT WITH HEALTHCARE ROYALTY PARTNERS FOR ELOBIXIBAT IN JAPAN \n* ALBIREO PHARMA INC - ‍ALBIREO SUBSIDIARY ELIGIBLE TO RECEIVE UP TO $60 MILLION UNDER AGREEMENT​ \n* ALBIREO PHARMA INC - ‍DECISION ON JAPANESE NEW DRUG APPLICATION FOR ELOBIXIBAT EXPECTED IN FIRST HALF OF 2018​ \n* ALBIREO PHARMA -HCR OBTAINS RIGHT TO RECEIVE ROYALTIES, SALES MILESTONES FOR ELOBIXIBAT IN JAPAN THAT MAY BE PAYABLE BY EA PHARMA, UP TO A THRESHOLD​ \n* ALBIREO PHARMA INC - ‍ELOBIX HAS RETAINED ITS RIGHT TO RECEIVE A MILESTONE PAYMENT FROM EA PHARMA IF ELOBIXIBAT IS APPROVED BY MHLW​ \n* ALBIREO PHARMA INC - ‍ IF SPECIFIED THRESHOLD IS REACHED, ELOBIX WILL AGAIN BECOME ELIGIBLE TO RECEIVE ROYALTIES AND SALES MILESTONES FOR ELOBIXIBAT Source text for Eikon:  ", "external_links": [], "published": "2018-01-03T15:08:00.000+02:00", "crawled": "2018-01-03T15:29:03.011+02:00", "highlightTitle": ""}